PML as a neuroprotective guardian: Leveraging nuclear protein quality control to mitigate neurotoxicity of an ALS ‐associated NEK1 variant
The FEBS Journal · 2026
DOI: 10.1111/febs.70630 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Tabea Stark und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry II, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, NIMA-Related Kinase 1, Promyelocytic Leukemia Protein. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Insoluble protein aggregates are a hallmark of neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ubiquitin–proteasome system (UPS) serves as a neuroprotective quality control mechanism that clears aggregates. PML nuclear bodies (NBs) were proposed to serve as hubs for SUMO‐primed ubiquitylation and degradation of misfolded proteins. Georgiadou et al. provide evidence that an ALS‐linked NEK1 truncation mutant is recruited to PML NBs, where it likely undergoes SUMOylation and ubiquitylation. In mice, PML loss exacerbates ALS‐like symptoms, while induced PML expression delays disease onset. These findings establish PML as a key regulator of proteostasis and highlight PML induction as a potential therapeutic strategy for ALS and related proteinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry II, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany.
- Cluster of Excellence SubCellular Architecture of Life (SCALE), Goethe University Frankfurt, Frankfurt, Germany.
ORCID-Profile: Stefan Müller
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Stark, T., & Müller, S. (2026). PML as a neuroprotective guardian: Leveraging nuclear protein quality control to mitigate neurotoxicity of an ALS ‐associated NEK1 variant. The FEBS Journal. https://doi.org/10.1111/febs.70630
Vancouver
Stark T, Müller S. PML as a neuroprotective guardian: Leveraging nuclear protein quality control to mitigate neurotoxicity of an ALS ‐associated NEK1 variant. The FEBS Journal. 2026. doi:10.1111/febs.70630
BibTeX
@article{Stark2026,
author = {Stark, Tabea and Müller, Stefan},
title = {PML as a neuroprotective guardian: Leveraging nuclear protein quality control to mitigate neurotoxicity of an ALS ‐associated NEK1 variant},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70630}
}
EUVIMED